Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Cash on Hand

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Jan 10, 2021 2:20pm

172 Views

Post# 32263595

RE:RE:RE:RE:RE:RE:RE:Cash on Hand

I'm not going to argue the semantics of value vs trading. Lets see if Dan actually delivers either a partnership or buyout. Dan has never failed to disappoint

The last time they said they have "cash on hand", they still ended up diluting. That risk still exists. For some this will be another entry point, for others theyre going to eat the dilution.

Hopefully this new hire can deliver in this year. But like MUGS said this will take time. ATE is likely dead money for the next 6 months.

3burtc wrote: That's incorrect! He said it should be trading 2 to 4 times more. He never said it was worth that. I think 346 is worth 20 billion dollars.

<< Previous

Bullboard Posts

Next >>

How Canadian investors can benefit from flow-through shares